<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131164">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01962077</url>
  </required_header>
  <id_info>
    <org_study_id>Nathalie- HMO-CTIL</org_study_id>
    <nct_id>NCT01962077</nct_id>
  </id_info>
  <brief_title>Comparison of MedCem MTA and Formocresol Used in Pulpotomies in Primary Teeth.</brief_title>
  <official_title>Comparison of MedCem MTA and Formocresol Used in Pulpotomies in Primary Teeth</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <authority>Ministry of Health - Director General: Israel</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      assess the effect of  MedCem MTA as a pulp medicament following pulpotomy in human primary
      molars with carious pulp exposure in comparison to Formocresol.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Success of MedCem MTA pulpotomy in primary molar</measure>
    <time_frame>Up to 36 mon</time_frame>
    <safety_issue>No</safety_issue>
    <description>No pain, no swelling or sinus tract, no internal root resorption progressing into the bone, no furcation and/or periapical bond destruction.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Effectiveness of MedCem MTAÂ® in Pulpotomies Primary Teeth</condition>
  <arm_group>
    <arm_group_label>MedCem MTA  pulpotomies</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MedCem MTA  pulpotomies in primary teeth.</intervention_name>
    <arm_group_label>MedCem MTA  pulpotomies</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. healthy children

          2. with Asymptomatic primary molars with a deep carious lesion;

          3. Exposure of a vital pulp by caries;

          4. No clinical or radiographic evidence of pulp degeneration, such as excessive bleeding
             from the root canal, internal root resorption, inter-radicular and/or periapical bone
             destruction,swelling, or sinus tract;

          5. Ability to perform a leakage free restoration of the teeth using stainless steel
             crown, or amalgam/resin based restoration.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Moti Moskovitz, DMD, PhD</last_name>
    <phone>972-2-6776168</phone>
    <email>motim@md.huji.ac.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hadassah Medical Organization</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hadas Lemberg, PhD</last_name>
      <phone>00 972 2 6777572</phone>
      <email>lhadas@hadassah.org.il</email>
    </contact>
    <investigator>
      <last_name>Moti Moskovitz, DMD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>October 10, 2013</lastchanged_date>
  <firstreceived_date>September 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pulpotomy</keyword>
  <keyword>MTA</keyword>
  <keyword>primary teeth</keyword>
  <keyword>formocresol</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
